Auckland City Hospital, Auckland, New Zealand.
Klinikum Hochsauerland GmbH, Arnsberg, Germany.
J Endovasc Ther. 2022 Aug;29(4):586-593. doi: 10.1177/15266028211059917. Epub 2021 Nov 20.
The purpose was to evaluate the safety and efficacy of the Serranator percutaneous transluminal angioplasty serration balloon catheter in patients with infrapopliteal peripheral artery disease.
A prospective, multicenter, single-arm feasibility study in 46 patients with claudication or chronic limb-threatening ischemia, Rutherford Clinical Category (RCC) 3 to 5, that required treatment of the infrapopliteal arteries above the tibiotalar joint. The primary efficacy outcome was device success-successful insertion, balloon inflation and deflation, and removal of the device(s) with a final diameter stenosis of <50%. The primary safety endpoint was a composite of major adverse limb events (MALE) and perioperative death (POD) through 30 day postprocedure. Other outcomes were change in RCC and ankle-brachial index, wound healing, and clinically-driven target lesion revascularization (CD-TLR). A subset of 9 patients were further evaluated by optical coherence tomography (OCT) or intravascular ultrasound (IVUS) for the presence of serrations in treated lesions. Patient follow-up occurred at 30 days and 6 months.
Forty-six patients received treatment with the Serranator device and 55 lesions were treated. Fifty-three lesions were deemed analyzable by the core lab with data and reported hereafter. Device success was 91.7% and freedom from MALE + POD through 30 days was 95.7%. Pretreatment stenosis of 82% was reduced to 21.8% and only 1 lesion (1.9%) required a bailout stent for a grade D dissection. The average maximum balloon inflation pressure was 6 atmospheres. Serrations were present in all treated lesions (n=10) in 9 patients imaged with OCT/IVUS as reviewed by the core laboratory. The RCC score improved by 1 or more level in 70% of patients at 6 months with 42% having a score of 0. The 6 month freedom from CD-TLR was 97.7%.
Serranator treatment of infrapopliteal lesions showed excellent lumen gain with minimal evidence of arterial injury and low 6 month CD-TLR. Imaging by IVUS and OCT showed serrations without significant dissection, supporting the device's proposed mechanism of action.
评估 Serranator 经皮腔内血管成形术切迹球囊导管在下肢动脉疾病患者中的安全性和疗效。
这是一项前瞻性、多中心、单臂可行性研究,纳入 46 名有间歇性跛行或慢性肢体威胁性缺血、Rutherford 临床分类(RCC)3 至 5 级、需要治疗胫距关节以上的下肢动脉疾病的患者。主要疗效终点为器械成功-成功插入、球囊充气和放气以及最终直径狭窄<50%的器械(多个)取出。主要安全性终点为 30 天内主要肢体不良事件(MALE)和围手术期死亡(POD)的复合终点。其他结局包括 RCC 和踝肱指数的变化、伤口愈合以及临床驱动的靶病变血运重建(CD-TLR)。9 名患者的一部分进一步通过光学相干断层扫描(OCT)或血管内超声(IVUS)评估治疗病变处的切迹。患者在 30 天和 6 个月时进行随访。
46 名患者接受 Serranator 器械治疗,55 处病变接受治疗。53 处病变由核心实验室进行数据分析,结果报告如下。器械成功率为 91.7%,30 天内无 MALE+POD 发生率为 95.7%。术前狭窄率为 82%,降低至 21.8%,仅 1 处病变(1.9%)因 D 型夹层需要挽救性支架置入。平均最大球囊充气压力为 6 个大气压。在接受 OCT/IVUS 检查的 9 名患者的所有治疗病变(n=10)中,核心实验室评估均存在切迹。6 个月时,70%的患者 RCC 评分提高 1 级或更高级别,42%的患者 RCC 评分为 0。6 个月无 CD-TLR 发生率为 97.7%。
Serranator 治疗下肢动脉病变可获得良好的管腔获得,动脉损伤最小,6 个月内 CD-TLR 发生率低。IVUS 和 OCT 成像显示存在切迹,但无明显夹层,支持器械的作用机制。